Zacks Research Issues Negative Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Research analysts at Zacks Research cut their Q1 2026 EPS estimates for shares of Sanofi in a note issued to investors on Wednesday, February 19th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $1.05 per share for the quarter, down from their previous forecast of $1.06. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.75 EPS and FY2027 earnings at $5.16 EPS.

A number of other analysts have also recently weighed in on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Up 0.6 %

Shares of Sanofi stock opened at $54.46 on Friday. The company has a fifty day moving average price of $50.95 and a 200 day moving average price of $52.52. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Hedge Funds Weigh In On Sanofi

A number of large investors have recently bought and sold shares of SNY. Price T Rowe Associates Inc. MD lifted its holdings in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the last quarter. Raymond James Financial Inc. bought a new position in Sanofi in the fourth quarter worth about $135,933,000. Boston Partners lifted its holdings in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Jennison Associates LLC lifted its holdings in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. Finally, Magnetar Financial LLC lifted its holdings in Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.